IP Library Granted Patent US 9,333,185
Granted Patent B2
US 9,333,185 · App. 14/386,731 · Granted May 10, 2016

Topically administered strontium-containing complexes for treating pain, pruritis and inflammation

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,333,185
App. No.
14/386,731
Granted
May 10, 2016
Kind
B2
Abstract

The present disclosure consists of therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations described herein perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Claims (27)

1. A composition comprising a complex of:

a divalent cationic strontium moiety;

a cysteine-based anti-oxidant moiety selected from the group consisting of: N-acetyl cysteine, and esters thereof; and

a polyhydroxyphenol moiety selected from the group consisting of: gallic acid and caffeic acid;

in a suitable carrier vehicle,

wherein the cysteine-based anti-oxidant moiety and the polyhydroxyphenol moiety are conjugated together by a thioester bond formed by a sulfhydryl group of the cysteine-based anti-oxidant moiety and a carboxyl group of the polyhydroxyphenol moiety.

2. The composition according to claim 1 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof.

3. The composition according to claim 1 , wherein the polyhydroxyphenol moiety is gallic acid.

4. The composition of claim 1 , wherein the cysteine-based anti-oxidant moiety is N-acetyl cysteine or esters thereof and the polyhydroxyphenol moiety is gallic acid.

5. The composition of claim 1 , wherein the strontium moiety is a strontium salt selected from the group consisting of: strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.

6. The composition according to claim 1 , further comprising a polymer.

7. The composition according to claim 6 , wherein the polymer is selected from the group consisting of: polyvinylpyrrolidone, cyclodextrins, carrageenan, alginic acid, xanthan gum, sulfated polysaccharides, pentosan polysulfate, chondroitin sulfate, dextran sulfate and heparin sulfate.

8. A composition comprising a complex of:

a divalent cationic strontium moiety;

a cysteine-based anti-oxidant moiety; and

a polyhydroxyphenol moiety;

wherein the cysteine-based anti-oxidant and the polyhydroxyphenol are conjugated together by a thioester bond between a sulfhydryl group of the cysteine-based anti-oxidant moiety and a carboxyl group of the polyhydroxyphenol moiety.

9. The composition according to claim 8 , wherein the cysteine-based anti-oxidant moiety is selected from the group consisting of: N-acetyl cysteine and esters thereof.

10. The composition according to claim 8 , wherein the polyhydroxyphenol moiety is selected from the group consisting of: gallic acid and caffeic acid.

11. The composition according to claim 8 , wherein the strontium moiety is a strontium salt selected from the group consisting of: strontium chloride, strontium chloride hexahydrate, strontium sulfate, strontium carbonate, strontium nitrate, strontium hydroxide, strontium hydrosulfide, strontium oxide, strontium acetate, strontium glutamate, strontium aspartate, strontium malonate, strontium maleate, strontium citrate, strontium threonate, strontium lactate, strontium pyruvate, strontium ascorbate, strontium alpha-ketoglutarate, and strontium succinate.

12. A composition comprising a complex of a strontium nitrate moiety, an N-acetyl cysteine moiety, and a gallic acid moiety; wherein the N-acetyl cysteine moiety and the gallic acid moiety are conjugated together by a thioester bond.

13. A method of treating pain in a subject comprising topically administering the compound of claim 1 to the subject.

14. A method of treating pruritus in a subject comprising topically administering the compound of claim 1 to the subject.

15. A method of treating pain in a subject comprising topically administering the compound of claim 8 to the subject.

16. A method of treating pruritus in a subject comprising topically administering the compound of claim 8 to the subject.

17. A method of treating pain in a subject comprising topically administering the compound of claim 12 to the subject.

18. A method of treating pruritus in a subject comprising topically administering the compound of claim 12 to the subject.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2018
From: PIKE, JOSEPH D.
To: GALLEON LABS LLC
Reel/Frame 046517/0804 →
COURT ORDER Recorded Jul 31, 2018
From: COSMEDERM BIOSCIENCE, INC.
To: JOSEPH D. PIKE
Reel/Frame 046717/0725 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2014
From: HAHN, GARY S.
To: COSMEDERM BIOSCIENCE, INC.
Reel/Frame 034060/0692 →